Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Director · Chief Executive Officer | May 05, 2025 | May 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date May 05, 2025 · Filed May 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 282,731.157 |
Reported balance
After 2025-05-05 transaction · row 1
1 source rowRow 1 · 2025-05-05 · Purchase · Acquired 34,000 · Balance 282,731.157 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2025 Filed May 6, 2025 17:58 UTC | Organon & Co. OGN · Entity 4115 | PurchaseCommon Stock | 34,000 | $8.81 | $299,370.00 |
DisclosureSEC source: 0001821825-25-000025 · wk-form4_1746554281.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,731.157 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 21,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · derivative · entry 11 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F7 · derivative.exercise_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. F7 · derivative.expiration_date: On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 38,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · derivative · entry 10 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,974 Underlying: Common Stock · 38,974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 48,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · derivative · entry 9 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,518 Underlying: Common Stock · 48,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F5 · derivative.exercise_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. F5 · derivative.expiration_date: On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 218,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · derivative · entry 8 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,267 Underlying: Common Stock · 218,267 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. F4 · derivative.expiration_date: The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 1,072,607 | $0.00 Strike: $14.89 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · derivative · entry 7 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072,607 Underlying: Common Stock · 1,072,607 shares Expires not disclosed F2 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. F2 · derivative.expiration_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 11,875 | $14.51 | $172,306.25 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 6 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,731.157 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 21,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,606.157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 21,553 | $14.51 | $312,734.03 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,134.157 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 38,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,687.157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 26,964 | $14.51 | $391,247.64 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,713.157 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:32 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 48,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000006 · wk-form4_1743629513.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,677.157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 8,529 | $15.29 | $130,408.41 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,919.157 F3 · balance_after: Includes the addition of 10,490.157 shares of Common Stock acquired from dividend reinvestments not previously reported. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 15,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,958 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 46,575 | $14.92 | $694,899.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,535 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 84,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,110 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:32 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 11,927 | $20.35 | $242,714.45 |
DisclosureSEC source: 0001821825-24-000102 · wk-form4_1725568313.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,888 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:32 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 21,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000102 · wk-form4_1725568313.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,815 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 22,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000062 · wk-form4_1715112373.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 12,256 | $19.61 | $240,340.16 |
DisclosureSEC source: 0001821825-24-000062 · wk-form4_1715112373.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,248 Read SEC document |
| May 04, 2024 Filed May 7, 2024 20:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 22,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000062 · wk-form4_1715112373.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 38,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · derivative · entry 6 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,948 Underlying: Common Stock · 38,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,472 Underlying: Common Stock · 21,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 21,553 | $18.80 | $405,196.40 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,343 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 38,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 11,874 | $18.80 | $223,231.20 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,923 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:29 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 599,128 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000033 · wk-form4_1712089757.xml · derivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,128 Underlying: Common Stock · 599,128 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:29 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 146,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000033 · wk-form4_1712089757.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,276 Underlying: Common Stock · 146,276 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 88,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,121 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 40,414 | $18.04 | $729,068.56 |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,326 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 88,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 22,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028095 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,161 Underlying: Common Stock · 22,158 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 12,254 | $24.24 | $297,036.96 |
DisclosureSEC source: 0001209191-23-028095 · doc4.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,619 Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 22,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028095 · doc4.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027170 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,711 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:05 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,491 | $24.63 | $36,723.33 |
DisclosureSEC source: 0001209191-23-027170 · doc4.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,715 Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:05 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027170 · doc4.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 419,847 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,847 Underlying: Common Stock · 419,847 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 116,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,921 Underlying: Common Stock · 116,921 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,943 Underlying: Common Stock · 21,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 11,895 | $23.09 | $274,655.55 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,495 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:13 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023073 · doc4.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:20 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 11,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014823 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,393 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:20 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 6,387 | $25.09 | $160,249.83 |
DisclosureSEC source: 0001209191-23-014823 · doc4.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,919 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:20 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 11,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014823 · doc4.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 22,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · derivative · entry 6 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,158 Underlying: Common Stock · 22,158 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 12,254 | $32.44 | $397,519.76 |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,913 Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 22,158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 Underlying: Common Stock · 2,631 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.